(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Pilot study to determine the therapeutic effect of two prarallel groups treated with either
Riciguat or Macitentan, evaluated by the change in systolic and diastolic RV function within
12 weeks after first drug intake in order to plan a larger Phase II study.
Phase:
Phase 2
Details
Lead Sponsor:
Philipps University Marburg Medical Center University of Giessen
Collaborators:
Coordination Center for Clinical Trials Marburg Philipps University Marburg Medical Center